Investor profile
RA Capital Management
RA Capital Management, L.P. is a Boston-based healthcare and life-sciences crossover investor, founded in 2004 by Vertex co-founder Richard Aldrich, investing across private and public markets. It leads seed and venture rounds, anchors IPOs, and provides follow-on public-market and structured capital. A separate Planetary Health Fund backs climate, minerals, energy, and agriculture companies with near-term commercialization paths. RA Capital pairs capital with in-house company-building teams, including its TechAtlas landscape-mapping engine, the Blackbird clinical-development accelerator, and the Raven biotech incubator. Reported scale: more than 250 employees and over $14B in assets under management. Locally, RA Capital co-led Slate Medicines' $130M Series A launch and participated in Incyclix Bio's Series B.
Directory portfolio
Companies connected here
3
Latest company funding first, including rounds involving other investors. Unknown dates last.
Slate Medicines
Latest company funding · Feb 24, 2026
Raleigh biotech developing therapeutics for migraine and other headache disorders. Lead program SLTE-1009 is a subcutaneous anti-PACAP monoclonal antibody in-licensed from DartsBio Pharmaceuticals, targeting a pathway distinct from CGRP.
- D
Dignify Therapeutics
Latest company funding · —
Develops on-demand drugs that let people with spinal cord injury and other neurological conditions empty the bladder or bowel when they choose. Lead candidate DTI-117, a short-acting peptide, received FDA clearance of its IND in October 2026 for a Phase 1 study funded by the NIH.
Incyclix Bio
Latest company funding · —
Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.